Navigation Links
Development of a CRF1 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System

Key words: CRF1 GPCR receptor binding assay LEADseeker SPA Imaging Beads


In the mammalian brain, the corticotrophin-releasing factor (CRF) system comprises four CRF-related peptides (CRF and urocortin 1, 2, and 3) and two G protein-coupled CRF receptor subtypes (CRF1 and CRF2, which includes CRF2α and CRF2β) (1). These receptor subtypes are positively coupled to adenylyl cyclase and show distinct expression patterns and binding characteristics. CRF1 receptors, for instance, are widely expressed in the brain, the anterior pituitary, and the GI tract (2). Strong evidence suggests that CRF1 receptors play an important role in stress responses and stress-related behaviors mediated through the hypothalamic-pituitary-adrenal (HPA) axis and through extra-hypothalamic systems (3).

This application note describes a 384-well CRF1 neuropeptide receptor binding assay developed using LEADseeker™ Multimodality Imaging System. The miniaturized assay is robust, achieving a Z’ value of 0.64, facilitating its adaptation to automated screening formats.


Materials
Products used

LEADseeker Multimodality Imaging System 18-1140-71

Wheat Germ Agglutinin (WGA) PS SPA RPNQ0260
Imaging Beads

[125I]Tyr0-CRF (ovine) IMQ20237


Other materials required
Human recombinant CRF1 receptor membrane preparation (Euroscreen)

Human urocortin 1 (Bachem)

Astressin (Tocris)

Costar™ solid white 384-well NBS™ coated microplate (Corning)

Protease-free BSA (Fluka)

EDTA-free protease inhibitor cocktail tablets (Roche)

Buffer: 25 mM Hepes pH 7.4
5 mM MgCl2
1 mM CaCl2
0.2% BSA (w/v) plus protease inhibitor cocktail

GraphPad Prism™ software v4.0 (GraphPad Software)


Protocol
Human recombinant CRF1 receptor membrane preparation was used in conjunction with [125I]Tyr0-CRF ligand and WGA PS SPA Imaging Beads. Non-specific binding (NSB) was determined in the presence of 200 nM urocortin. The standard assay format was as follows:

1) Reagents were added in the following order: buffer, unlabeled ligand (NSB wells) labeled ligand, membrane, and bead. Total assay volume was 50 µl.

2) Wells contained 10 µl of 1.5 nM [125I]Tyr0-CRF (final concentration 0.3 nM) unless otherwise stated. Wells also contained 0.3 µg of membrane and 30 µg of beads, which were added in 10 µl volumes.

3) NSB wells contained 10 µl of 1000 nM urocortin (final concentration 200 nM) in addition to the above.

4) Plates were sealed and incubated in darkness for 18 h at room temperature (20–25 °C).

5) Following incubation, plates were imaged on LEADseeker Multimodality Imaging System for 5 min using quasi-coincident averaging and 3 ×3 binning.


Results
Kd determination
Saturation binding was performed with dilutions of [125I]Tyr0-CRF to give a range of concentrations from 0.06 to 4.96 nM in the wells. Figure 1 shows the saturation curve, which was fitted using non-linear regression with the data analysis s oftware package GraphPad Prism v4.0. A Kd value of 0.4 nM (95% confidence intervals 0.3–0.5 nM) was estimated directly from the curve.

IC50 determination
Competitive binding of 0.3 nM [125I]Tyr0-CRF with urocortin (Fig 2A) and astressin (Fig 2B) was assessed and the IC50 value of each ligand calculated. Final concentrations in the wells were 0.039–160 nM and 0.005–500 nM respectively. Two separate batches of [125I]Tyr0-CRF were used for these evaluations, each with significantly different specific activities. This is demonstrated by the increase in specific IODs shown in Figure 2B. The IC50 value for urocortin was determined to be 3.5 nM (95% confidence interval range 2.7–4.5 nM) and the Ki value was 1.9 nM (95% confidence intervals 1.5–2.5 nM). The 50 value for astressin was 1.2 nM (95% confidence interval range 1.1–1.3 nM) and the Ki value was 0.6 nM (95% confidence intervals 0.6–0.7 nM).

Z’ analysis
Finally, a Z’ analysis was performed using 66 replicate values for “total” and NSB wells (4). The Z’ value indicated by Figure 3 is 0.64, which was well within the acceptable Z’ value range (0.5–1.0) and confirmed the robustness of the assay.


References
1. Steckler, T. and Holsboer, F. Biological Psychiatry 46, 1480–1508 (1999).

2. Hauger, R. L. et al. Pharmacological Review 55, 21–26 (2003).

3. Timpl, P. et al. Nature Genetics 19, 162–166 (1998).

4. Zhang, J. et al. Journal Biomolecular Screening 4 (2), 67–73 (1999).



back to top
'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. The let-7 microRNA Family Regulates RAS: Implications for Development and Oncogenesis
2. Rapid Method Development With the BioLogic DuoFlow Chromatography System for the Purification of His-Tagged Proteins
3. A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis
4. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
5. Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System
6. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
7. Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
8. Development of an adrenergic α2a receptor binding assay using the LEADseeker Multimodality Imaging System
9. Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets.
10. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
11. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... 2016  Renova™ Therapeutics, a biotechnology company developing ... other chronic diseases, announced that Catherine Bovenizer ... Financial Officer (CFO), effective today. Ms. ... experience in financial management for a variety of ... Most recently, Ms. Bovenizer was the Vice President ...
(Date:12/5/2016)... -- The U.S. Biotechnology industry is the ... revenue and some $890 billion of total market value. In ... and this figure is expected to exceed $220 billion ... four equities for assessment: Northwest Biotherapeutics Inc. (NASDAQ: ... ACAD ), Acorda Therapeutics Inc. (NASDAQ: ACOR ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... resume cervical and lumbar disc production, company President, Jake Lubinski will be traveling ... implanting the AxioMed disc in Bern, Lucerne, and Zurich to discuss the benefits ...
(Date:12/2/2016)... , Dec 2, 2016 Research ... report "Nanobiotechnology Applications, Markets and Companies" to their ... , , ... nanobiotechnology by the pharmaceutical and biotechnology industries is anticipated. Nanotechnology ... from formulations for optimal delivery to diagnostic applications in clinical ...
Breaking Biology Technology:
(Date:11/14/2016)... SARASOTA, Fla., Nov. 14, 2016  xG Technology, Inc. ... in providing critical wireless communications for use in challenging ... ended September 30, 2016. Management will hold a conference ... at 5:00 p.m. Eastern Time (details below). ... announced a $16 million binding agreement to acquire Vislink ...
(Date:6/22/2016)... , June 22, 2016 On Monday, ... call to industry to share solutions for the Biometric ... U.S. Customs and Border Protection (CBP), explains that CBP ... are departing the United States , ... and to defeat imposters. Logo - ...
(Date:6/9/2016)... attendance control systems is proud to announce the introduction of fingerprint attendance control software, ... employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
Breaking Biology News(10 mins):